Vonaprument

Phase 3Small molecule

AAnnexon, Inc.

Vonaprument is one of 12 small molecule programs targeting Geographic Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyActive, not recruiting

Geographic AtrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Tecfidera

Biogen

Phase 2

1 5

Farxiga

AstraZeneca

Phase 2

1 6

Tinlarebant

BBelite Bio, Inc

Phase 3

1 7

Vonaprument

AAnnexon, Inc.

Phase 3

2 8

Opregen

Roche

Phase 2

1 9

JNJ-81201887

Johnson & Johnson

Phase 2

1 10

BS01

BBionic Sight LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Geographic Atrophy

NCT06510816

Q3 2029

Phase 3Not yet recruiting

Geographic Atrophy

NCT07807969

Clinical

Trials by Indication[1]

Geographic Atrophy2 trials

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

Active, not recruiting·AAnnexon, Inc.·Phase 3·NCT06510816·659 enrolled

A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy

Not yet recruiting·AAnnexon, Inc.·Phase 3·NCT07807969·605 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vonaprument. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vonaprument compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vonaprument. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Annexon, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAnnexon, Inc.

Vonaprument

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Geographic Atrophy2 trials

References

Drug Info

Quick Facts

Related News